1. Home
  2. CBIO vs STRT Comparison

CBIO vs STRT Comparison

Compare CBIO & STRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$11.18

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Logo STRATTEC SECURITY CORPORATION

STRT

STRATTEC SECURITY CORPORATION

N/A

Current Price

$74.00

Market Cap

378.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
STRT
Founded
2003
1908
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
389.7M
378.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CBIO
STRT
Price
$11.18
$74.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$26.67
N/A
AVG Volume (30 Days)
162.2K
32.4K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.53
EPS
N/A
3.26
Revenue
N/A
$439,195,000.00
Revenue This Year
N/A
$4.22
Revenue Next Year
N/A
$2.04
P/E Ratio
N/A
$23.90
Revenue Growth
N/A
5.24
52 Week Low
$8.72
$31.71
52 Week High
$17.39
$92.50

Technical Indicators

Market Signals
Indicator
CBIO
STRT
Relative Strength Index (RSI) 47.95 28.97
Support Level $10.45 $72.01
Resistance Level $13.37 $82.98
Average True Range (ATR) 0.94 2.82
MACD 0.00 -1.60
Stochastic Oscillator 20.03 3.92

Price Performance

Historical Comparison
CBIO
STRT

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About STRT STRATTEC SECURITY CORPORATION

Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.

Share on Social Networks: